UroGen Pharma URGN reported its Q3 earnings results on Tuesday, November 14, 2023 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
UroGen Pharma beat estimated earnings by 20.0%, reporting an EPS of $-0.68 versus an estimate of $-0.85.
Revenue was up $4.75 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.11 which was followed by a 4.48% increase in the share price the next day.
Here's a look at UroGen Pharma's past performance:
Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
---|---|---|---|---|
EPS Estimate | -1.14 | -1.33 | -1.07 | -1.16 |
EPS Actual | -1.03 | -1.30 | -1.22 | -1.13 |
Revenue Estimate | 20.12M | 17.18M | 18.51M | 20.15M |
Revenue Actual | 21.14M | 17.19M | 18.09M | 16.10M |
To track all earnings releases for UroGen Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.